Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Faes Farma","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hikma and FAES Farma Enter Into Exclusive Licensing Agreement for The Commercialisation of Bilastine Tablets In The US","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Vivimed Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vivimed Labs Gets Approval from Uzbekistan Govt for Two Products","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved"},{"orgOrder":0,"company":"Aralez Pharmaceuticals","sponsor":"Miravo Healthcare","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Miravo Healthcare\u2122 Announces the Canadian Commercial Launch of Blexten\u00ae for Patients 4 Years of Age and Older*","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Market Launch: Tiefenbacher Pharmaceuticals Successfully Launches First Generic Version of The Antihistamine Bilastine","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Bilastine

    Menu

    Bilastine

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Tiefenbacher Group

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Contact Supplier Contact Supplier
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              New Market Launch: Tiefenbacher Pharmaceuticals Successfully Launches First Generic Version of The Antihistamine Bilastine

              Details:

              Bilastine is an innovative anti-allergy medicine improving the life of patients suffering from allergic symptoms also a second-generation antihistamine product helps to relieve nasal and non-nasal symptoms of seasonal rhinitis as well as urticaria caused symptoms.

              Lead Product(s): Bilastine

              Therapeutic Area: Immunology Product Name: Bilastine-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 20, 2021

              Tiefenbacher Compnay Banner

              Iran Expo

              Not Confirmed

              envelop Contact Supplier

              Aralez Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Miravo Healthcare™ Announces the Canadian Commercial Launch of Blexten® for Patients 4 Years of Age and Older*

              Details:

              Blexten (bilastine) is a second-generation antihistamine drug, exerts its effect through its highly selective inhibition of peripheral histamine H1 receptors for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria.

              Lead Product(s): Bilastine

              Therapeutic Area: Immunology Product Name: Blexten

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Miravo Healthcare

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Faes Farma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Hikma and FAES Farma Enter Into Exclusive Licensing Agreement for The Commercialisation of Bilastine Tablets In The US

              Details:

              Under the terms of the agreement, Hikma will be responsible for obtaining regulatory approval of Bilastine by the US Food and Drug Administration (FDA) and for the commercialisation of the product in the US following approval.

              Lead Product(s): Bilastine

              Therapeutic Area: Immunology Product Name: Bilaxten

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Hikma Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement September 20, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Vivimed Labs

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vivimed Labs Gets Approval from Uzbekistan Govt for Two Products

              Details:

              The company has received approval for Bilastin tablets, which are used for the treatment of allergic Rhino conjunctivitis and Urticaria, the Hyderabad-based company said in a regulatory filing.

              Lead Product(s): Bilastine

              Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 08, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Zhejiang Bilastine
              Athena Bilastine
              Close
              4
              Post Enquiry
              POST ENQUIRY